Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Jul;80(10):1617–1622. doi: 10.1038/sj.bjc.6690571

Expression and up-regulation of interleukin-6 in oesophageal carcinoma cells by n-sodium butyrate

L-S Wang 1, K-C Chow 2, C-W Wu 3
PMCID: PMC2363087  PMID: 10408408

Abstract

Recently, the serum level of interleukin (IL)-6 has been shown to correlate with disease progression and prognosis of cancer patients. However, the available information about the source and the pathophysiological regulation of IL-6 in cancer cells is limited. Thus, in this study, we tried to identify the source and the clinical roles of serum IL-6 in patients with oesophageal squamous cell carcinoma (ESCC), and then further to characterize the biological regulation of IL-6 in ESCC cell lines. Sera and tissue specimens from 80 consecutive patients with ESCC were collected between 1993 and 1997. Additionally, three ESCC cell lines were used for in vitro study. The concentration of serum IL-6 was measured by enzyme-linked immunosorbent assay (ELISA), and correlated the survival time with measured IL-6 level. Expressions of IL-6, IL-6Rα (IL-6 receptor alpha) and gp130 in pathological sections and cell lines were characterized by immunological staining. Detection of IL-6 mRNA was determined by in situ hybridization (ISH) and reverse transcription-polymerase chain reaction (RT-PCR). Up-regulation of IL-6 by n-sodium butyrate (n-BT) was studied in ESCC cell lines. The levels of serum IL-6 in patients with ESCC were significantly higher than those in the healthy controls. Serum levels of IL-6 were also shown to correlate with disease progression and survival. However, sCD8 levels and lymphocyte counts in the peripheral blood were not parallel to the changed pattern of serum IL-6. In pathological sections and ESCC cell lines, message of IL-6 was identified by ISH in cancer cells. Expression of IL-6 mRNA was further confirmed with RT-PCR in ESCC cell lines. Although IL-6 was detected in some ESCC cell lines, IL-6 gene expression and protein production could be induced or enhanced by n-BT treatment in all three cell lines. The serum levels of IL-6 are frequently elevated at diagnosis of ESCC, and are associated with poor prognosis. IL-6 that could be produced by cancer cells is up-regulated by n-BT. © 1999 Cancer Research Campaign

Keywords: oesophageal carcinoma, interleukin-6, sodium butyrate, up-regulation

Full Text

The Full Text of this article is available as a PDF (196.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baba M., Hasegawa H., Nakayabu M., Shimizu N., Suzuki S., Kamada N., Tani K. Establishment and characteristics of a gastric cancer cell line (HuGC-OOHIRA) producing high levels of G-CSF, GM-CSF, and IL-6: the presence of autocrine growth control by G-CSF. Am J Hematol. 1995 Jul;49(3):207–215. doi: 10.1002/ajh.2830490306. [DOI] [PubMed] [Google Scholar]
  2. Blay J. Y., Negrier S., Combaret V., Attali S., Goillot E., Merrouche Y., Mercatello A., Ravault A., Tourani J. M., Moskovtchenko J. F. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992 Jun 15;52(12):3317–3322. [PubMed] [Google Scholar]
  3. Castell J. V., Gómez-Lechón M. J., David M., Fabra R., Trullenque R., Heinrich P. C. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990 Nov;12(5):1179–1186. doi: 10.1002/hep.1840120517. [DOI] [PubMed] [Google Scholar]
  4. Chiu C. F., Chow K. C., Lin F. M., Lin C. K., Liu S. M., Chen K. Y. Expression of DNA topoisomerase II alpha and multidrug resistance p-glycoprotein in acute leukemia. Zhonghua Yi Xue Za Zhi (Taipei) 1997 Oct;60(4):184–190. [PubMed] [Google Scholar]
  5. Chow K. C., Nacilla J. Q., Witzig T. E., Li C. Y. Is persistent polyclonal B lymphocytosis caused by Epstein-Barr virus? A study with polymerase chain reaction and in situ hybridization. Am J Hematol. 1992 Dec;41(4):270–275. doi: 10.1002/ajh.2830410409. [DOI] [PubMed] [Google Scholar]
  6. Gauldie J., Richards C., Harnish D., Lansdorp P., Baumann H. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A. 1987 Oct;84(20):7251–7255. doi: 10.1073/pnas.84.20.7251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Inoue M., Minami M., Fujii Y., Matsuda H., Shirakura R., Kido T. Granulocyte colony-stimulating factor and interleukin-6-producing lung cancer cell line, LCAM. J Surg Oncol. 1997 Apr;64(4):347–350. doi: 10.1002/(sici)1096-9098(199704)64:4<347::aid-jso18>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  8. Kabir S., Daar G. A. Serum levels of interleukin-1, interleukin-6 and tumour necrosis factor-alpha in patients with gastric carcinoma. Cancer Lett. 1995 Aug 16;95(1-2):207–212. doi: 10.1016/0304-3835(95)03895-4. [DOI] [PubMed] [Google Scholar]
  9. Katlic M. R., Wilkins E. W., Jr, Grillo H. C. Three decades of treatment of esophageal squamous carcinoma at the Massachusetts General Hospital. J Thorac Cardiovasc Surg. 1990 May;99(5):929–938. [PubMed] [Google Scholar]
  10. Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988 Mar 3;332(6159):83–85. doi: 10.1038/332083a0. [DOI] [PubMed] [Google Scholar]
  11. Kishimoto T. The biology of interleukin-6. Blood. 1989 Jul;74(1):1–10. [PubMed] [Google Scholar]
  12. Lee J. D., Sievers T. M., Skotzko M., Chandler C. F., Morton D. L., McBride W. H., Economou J. S. Interleukin-6 production by human melanoma cell lines. Lymphokine Cytokine Res. 1992 Jun;11(3):161–166. [PubMed] [Google Scholar]
  13. Liu C. C., Fahn H. J., Li W. Y., Wu Y. C., Huang M. H., Wang L. S. Lymph node metastasis in squamous cell carcinoma of the intrathoracic esophagus. Zhonghua Yi Xue Za Zhi (Taipei) 1998 Feb;61(2):77–84. [PubMed] [Google Scholar]
  14. Miki S., Iwano M., Miki Y., Yamamoto M., Tang B., Yokokawa K., Sonoda T., Hirano T., Kishimoto T. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 1989 Jul 3;250(2):607–610. doi: 10.1016/0014-5793(89)80805-1. [DOI] [PubMed] [Google Scholar]
  15. Ni K., O'Neill H. C. Proliferation of the BCL1 B cell lymphoma induced by IL-4 and IL-5 is dependent on IL-6 and GM-CSF. Immunol Cell Biol. 1992 Oct;70(Pt 5):315–322. doi: 10.1038/icb.1992.40. [DOI] [PubMed] [Google Scholar]
  16. Obata N. H., Tamakoshi K., Shibata K., Kikkawa F., Tomoda Y. Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. Anticancer Res. 1997 Jan-Feb;17(1A):337–342. [PubMed] [Google Scholar]
  17. Oka M., Yamamoto K., Takahashi M., Hakozaki M., Abe T., Iizuka N., Hazama S., Hirazawa K., Hayashi H., Tangoku A. Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res. 1996 Jun 15;56(12):2776–2780. [PubMed] [Google Scholar]
  18. Peto R., Pike M. C. Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data. Biometrics. 1973 Sep;29(3):579–584. [PubMed] [Google Scholar]
  19. Ray A., Tatter S. B., May L. T., Sehgal P. B. Activation of the human "beta 2-interferon/hepatocyte-stimulating factor/interleukin 6" promoter by cytokines, viruses, and second messenger agonists. Proc Natl Acad Sci U S A. 1988 Sep;85(18):6701–6705. doi: 10.1073/pnas.85.18.6701. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Reichner J. S., Mulligan J. A., Palla M. E., Hixson D. C., Albina J. E., Bland K. I. Interleukin-6 production by rat hepatocellular carcinoma cells is associated with metastatic potential but not with tumorigenicity. Arch Surg. 1996 Apr;131(4):360–365. doi: 10.1001/archsurg.1996.01430160018002. [DOI] [PubMed] [Google Scholar]
  21. Scambia G., Testa U., Benedetti Panici P., Foti E., Martucci R., Gadducci A., Perillo A., Facchini V., Peschle C., Mancuso S. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer. 1995 Feb;71(2):354–356. doi: 10.1038/bjc.1995.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Seymour J. F., Talpaz M., Hagemeister F. B., Cabanillas F., Kurzrock R. Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease. Am J Med. 1997 Jan;102(1):21–28. doi: 10.1016/s0002-9343(96)00352-x. [DOI] [PubMed] [Google Scholar]
  23. Stein T. P., Koerner B., Schluter M. D., Leskiw M. J., Gaprindachvilli T., Richards E. W., Cope F. O., Condolucci D. Weight loss, the gut and the inflammatory response in aids patients. Cytokine. 1997 Feb;9(2):143–147. doi: 10.1006/cyto.1996.0148. [DOI] [PubMed] [Google Scholar]
  24. Stephanou A., Knight R. A., Annicchiarico-Petruzzelli M., Finazzi-Agrò A., Lightmann S. L., Melino G. Interleukin-1 beta and interleukin-6 mRNA are expressed in human glioblastoma and neuroblastoma cells respectively. Funct Neurol. 1992 Mar-Apr;7(2):129–133. [PubMed] [Google Scholar]
  25. Strassmann G., Fong M., Kenney J. S., Jacob C. O. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest. 1992 May;89(5):1681–1684. doi: 10.1172/JCI115767. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Strassmann G., Jacob C. O., Evans R., Beall D., Fong M. Mechanisms of experimental cancer cachexia. Interaction between mononuclear phagocytes and colon-26 carcinoma and its relevance to IL-6-mediated cancer cachexia. J Immunol. 1992 Jun 1;148(11):3674–3678. [PubMed] [Google Scholar]
  27. Tabibzadeh S. S., Poubouridis D., May L. T., Sehgal P. B. Interleukin-6 immunoreactivity in human tumors. Am J Pathol. 1989 Sep;135(3):427–433. [PMC free article] [PubMed] [Google Scholar]
  28. Taga T., Hibi M., Hirata Y., Yamasaki K., Yasukawa K., Matsuda T., Hirano T., Kishimoto T. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell. 1989 Aug 11;58(3):573–581. doi: 10.1016/0092-8674(89)90438-8. [DOI] [PubMed] [Google Scholar]
  29. Takeuchi E., Ito M., Mori M., Yamaguchi T., Nakagawa M., Yokota S., Nishikawa H., Sakuma-Mochizuki J., Hayashi S., Ogura T. Lung cancer producing interleukin-6. Intern Med. 1996 Mar;35(3):212–214. doi: 10.2169/internalmedicine.35.212. [DOI] [PubMed] [Google Scholar]
  30. Takizawa H., Ohtoshi T., Ohta K., Yamashita N., Hirohata S., Hirai K., Hiramatsu K., Ito K. Growth inhibition of human lung cancer cell lines by interleukin 6 in vitro: a possible role in tumor growth via an autocrine mechanism. Cancer Res. 1993 Sep 15;53(18):4175–4181. [PubMed] [Google Scholar]
  31. Tamura S., Ouchi K. F., Mori K., Endo M., Matsumoto T., Eda H., Tanaka Y., Ishitsuka H., Tokita H., Yamaguchi K. Involvement of human interleukin 6 in experimental cachexia induced by a human uterine cervical carcinoma xenograft. Clin Cancer Res. 1995 Nov;1(11):1353–1358. [PubMed] [Google Scholar]
  32. Tanner J., Tosato G. Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice. J Clin Invest. 1991 Jul;88(1):239–247. doi: 10.1172/JCI115283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Van Meir E., Sawamura Y., Diserens A. C., Hamou M. F., de Tribolet N. Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer Res. 1990 Oct 15;50(20):6683–6688. [PubMed] [Google Scholar]
  34. Walker P. R., Saas P., Dietrich P. Y. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol. 1997 May 15;158(10):4521–4524. [PubMed] [Google Scholar]
  35. Wang L. S., Chi K. H., Hu M. H., Fahn H. J., Huang M. H. Management for patients with advanced T4 epidermoid carcinoma of the esophagus. J Surg Oncol. 1996 May;62(1):22–29. doi: 10.1002/(SICI)1096-9098(199605)62:1<22::AID-JSO5>3.0.CO;2-T. [DOI] [PubMed] [Google Scholar]
  36. Wang L. S., Huang M. H., Huang B. S., Chien K. Y. Gastric substitution for resectable carcinoma of the esophagus: an analysis of 368 cases. Ann Thorac Surg. 1992 Feb;53(2):289–294. doi: 10.1016/0003-4975(92)91335-7. [DOI] [PubMed] [Google Scholar]
  37. Wang L. S., Lin H. Y., Chang C. J., Fahn H. J., Huang M. H., Lin C. F. Effects of en bloc esophagectomy on nutritional and immune status in patients with esophageal carcinoma. J Surg Oncol. 1998 Feb;67(2):90–98. doi: 10.1002/(sici)1096-9098(199802)67:2<90::aid-jso4>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  38. Watson J. M., Sensintaffar J. L., Berek J. S., Martínez-Maza O. Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res. 1990 Nov 1;50(21):6959–6965. [PubMed] [Google Scholar]
  39. Wojciechowska-Lacka A., Matecka-Nowak M., Adamiak E., Lacki J. K., Cerkaska-Gluszak B. Serum levels of interleukin-10 and interleukin-6 in patients with lung cancer. Neoplasma. 1996;43(3):155–158. [PubMed] [Google Scholar]
  40. Wong G. G., Witek-Giannotti J., Hewick R. M., Clark S. C., Ogawa M. Interleukin 6: identification as a hematopoietic colony-stimulating factor. Behring Inst Mitt. 1988 Aug;(83):40–47. [PubMed] [Google Scholar]
  41. Wu C. W., Wang S. R., Chao M. F., Wu T. C., Lui W. Y., P'eng F. K., Chi C. W. Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol. 1996 Jul;91(7):1417–1422. [PubMed] [Google Scholar]
  42. Wu Y. K., Chen P. T., Fang J. P., Lin S. S. Surgical treatment of esophageal carcinoma. Am J Surg. 1980 Jun;139(6):805–809. doi: 10.1016/0002-9610(80)90386-4. [DOI] [PubMed] [Google Scholar]
  43. Yamasaki K., Taga T., Hirata Y., Yawata H., Kawanishi Y., Seed B., Taniguchi T., Hirano T., Kishimoto T. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science. 1988 Aug 12;241(4867):825–828. doi: 10.1126/science.3136546. [DOI] [PubMed] [Google Scholar]
  44. Yamashita S., Ogawa M., Abe T., Yamashita J., Sakamoto K., Niwa H., Yamamura K. Group II phospholipase A2 in invasive gastric cancer cell line is induced by interleukin 6. Biochem Biophys Res Commun. 1994 Feb 15;198(3):878–884. doi: 10.1006/bbrc.1994.1125. [DOI] [PubMed] [Google Scholar]
  45. Yanagawa H., Sone S., Takahashi Y., Haku T., Yano S., Shinohara T., Ogura T. Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer. 1995 May;71(5):1095–1098. doi: 10.1038/bjc.1995.212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Zhang Y., Lin J. X., Vilcek J. Synthesis of interleukin 6 (interferon-beta 2/B cell stimulatory factor 2) in human fibroblasts is triggered by an increase in intracellular cyclic AMP. J Biol Chem. 1988 May 5;263(13):6177–6182. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES